Have your own idea? Try our Stock Screener
Chinese (SSE) Biotech Industry Analysis
UpdatedJul 08, 2026
DataAggregated Company Financials
Companies75
- 7D4.1%
- 3M-15.5%
- 1Y-20.5%
- YTD-18.1%
The Biotech industry is up 8.8% in the last week, with Gan & Lee Pharmaceuticals up 15%. During this same period, the Chengdu Olymvax Biopharmaceuticals underperformed, falling 5.4%. In contrast, the industry has lost 17% in the last 12 months. Looking forward, earnings are forecast to grow by 28% annually.
Industry Valuation and Performance
Has the Chinese Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Wed, 08 Jul 2026 | CN¥787.8b | CN¥109.9b | -CN¥8,630,064,105.00 | 50x | -91.3x | 7.2x |
| Fri, 05 Jun 2026 | CN¥764.7b | CN¥109.9b | -CN¥8,605,265,559.00 | 47.8x | -88.9x | 7x |
| Sun, 03 May 2026 | CN¥878.8b | CN¥107.9b | -CN¥9,450,648,500.00 | 55x | -93x | 8.1x |
| Tue, 31 Mar 2026 | CN¥901.2b | CN¥109.9b | CN¥4.8b | 44.6x | 186.7x | 8.2x |
| Thu, 26 Feb 2026 | CN¥936.8b | CN¥106.5b | CN¥3.9b | 48.3x | 240.7x | 8.8x |
| Sat, 24 Jan 2026 | CN¥972.5b | CN¥106.1b | CN¥3.8b | 52.9x | 257.8x | 9.2x |
| Mon, 22 Dec 2025 | CN¥935.5b | CN¥106.1b | CN¥3.8b | 48.2x | 248x | 8.8x |
| Wed, 19 Nov 2025 | CN¥1.0t | CN¥106.1b | CN¥3.8b | 48.3x | 265.3x | 9.4x |
| Fri, 17 Oct 2025 | CN¥949.0b | CN¥107.5b | CN¥5.0b | 49.4x | 188.3x | 8.8x |
| Sun, 14 Sep 2025 | CN¥1.0t | CN¥107.6b | CN¥5.1b | 50.6x | 197x | 9.4x |
| Tue, 12 Aug 2025 | CN¥980.4b | CN¥113.4b | CN¥8.3b | 41.7x | 118.2x | 8.6x |
| Thu, 10 Jul 2025 | CN¥889.7b | CN¥112.9b | CN¥8.2b | 39.7x | 108x | 7.9x |
| Sat, 07 Jun 2025 | CN¥892.8b | CN¥113.1b | CN¥8.2b | 36x | 108.5x | 7.9x |
| Mon, 05 May 2025 | CN¥807.0b | CN¥113.7b | CN¥7.7b | 34.3x | 105.2x | 7.1x |
| Wed, 02 Apr 2025 | CN¥871.0b | CN¥136.1b | CN¥11.7b | 32.6x | 74.7x | 6.4x |
| Fri, 28 Feb 2025 | CN¥858.0b | CN¥136.3b | CN¥11.0b | 33.8x | 78x | 6.3x |
| Sun, 26 Jan 2025 | CN¥798.8b | CN¥136.0b | CN¥10.8b | 32.2x | 74.3x | 5.9x |
| Tue, 24 Dec 2024 | CN¥852.4b | CN¥136.0b | CN¥10.8b | 32.6x | 79.2x | 6.3x |
| Thu, 21 Nov 2024 | CN¥933.1b | CN¥141.7b | CN¥11.2b | 37.5x | 83.3x | 6.6x |
| Sat, 19 Oct 2024 | CN¥908.3b | CN¥154.1b | CN¥14.5b | 38.3x | 62.9x | 5.9x |
| Mon, 16 Sep 2024 | CN¥737.3b | CN¥154.1b | CN¥14.5b | 30.8x | 50.8x | 4.8x |
| Wed, 14 Aug 2024 | CN¥827.9b | CN¥161.2b | CN¥17.3b | 31.4x | 47.9x | 5.1x |
| Fri, 12 Jul 2024 | CN¥829.6b | CN¥161.1b | CN¥17.3b | 32.6x | 48x | 5.1x |
| Sun, 09 Jun 2024 | CN¥877.3b | CN¥161.1b | CN¥17.3b | 31.5x | 50.7x | 5.4x |
| Tue, 07 May 2024 | CN¥985.1b | CN¥161.2b | CN¥17.3b | 36.8x | 57.1x | 6.1x |
| Thu, 04 Apr 2024 | CN¥965.0b | CN¥161.0b | CN¥20.1b | 39.9x | 47.9x | 6x |
| Sat, 02 Mar 2024 | CN¥1.0t | CN¥165.5b | CN¥22.0b | 36.4x | 45.8x | 6.1x |
| Mon, 29 Jan 2024 | CN¥964.3b | CN¥167.9b | CN¥21.4b | 35.1x | 45x | 5.7x |
| Wed, 27 Dec 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 39.4x | 50.8x | 6.5x |
| Fri, 24 Nov 2023 | CN¥1.1t | CN¥168.1b | CN¥21.5b | 41.8x | 52.6x | 6.7x |
| Sun, 22 Oct 2023 | CN¥1.0t | CN¥171.1b | CN¥25.3b | 39.1x | 40.3x | 6x |
| Tue, 19 Sep 2023 | CN¥1.0t | CN¥170.9b | CN¥25.2b | 39.3x | 41.5x | 6.1x |
| Thu, 17 Aug 2023 | CN¥1.0t | CN¥173.8b | CN¥28.1b | 38.4x | 37x | 6x |
| Sat, 15 Jul 2023 | CN¥1.1t | CN¥177.2b | CN¥29.9b | 39.7x | 35.8x | 6x |
Price to Earnings Ratio
35.8x
Current Industry PE
- Investors are relatively neutral on the Chinese Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 6.9x.
Past Earnings Growth
- Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
- Revenues have also declined 15% per year, which is driving profits down.
Industry Trends
Which industries have driven the changes within the Chinese Healthcare industry?
| CN Market | -4.33% | |
| Healthcare | 2.96% | |
| Biotech | 4.10% | |
| Biotech | 4.10% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 603087 Gan & Lee Pharmaceuticals | CN¥62.85 | 8.3% +CN¥2.9b | 14.3% | PE36.5x | |
| 600201 Jinyu Bio-technology | CN¥12.57 | 6.5% +CN¥841.4m | 57.5% | PE131.7x | |
| 688767 Hangzhou Biotest BiotechLtd | CN¥38.49 | 13.2% +CN¥657.0m | 9.5% | PE185.8x | |
| 688192 Dizal (Jiangsu) Pharmaceutical | CN¥45.18 | 3.1% +CN¥637.3m | -29.6% | PS23.5x | |
| 000518 Jiangsu Sihuan Bioengineering | CN¥3.82 | 13.0% +CN¥453.0m | 54.0% | PS10.3x |